Bio-Path Holdings, Inc. (NASDAQ: BPTH) experienced a remarkable surge in premarket trading on Monday, following a substantial climb of nearly 7% on Friday. The stock soared an astounding 62%, reaching a high of $3.38 during early premarket hours, compared to its Friday price of $1.93. This surge was accompanied by a notable trading volume of 1.5 million shares, indicating considerable bullish sentiment in extended trading.
- Promising Bio-Path Phase 2 Data
- Optimistic Prospects
- Conclusion
Promising Bio-Path Phase 2 Data
This surge comes on the heels of promising phase 2 data presented by Bio-Path at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. The company's lead product candidate, prexigebersen (BP1001), demonstrated compelling efficacy results in two reporting cohorts of acute myeloid leukemia (AML) patients. In Cohort 1, which included newly diagnosed patients, 75% of evaluable patients achieved complete remission (CR), CRh, or CRi, while in Cohort 2, comprising relapsed/refractory patients, 55% achieved CR/CRi/CRh.
Optimistic Prospects
Maro Ohanian, D.O., from the University of Texas MD Anderson Cancer Center, presented the data, highlighting prexigebersen's well-tolerated nature and its potential to address the unmet needs of vulnerable cancer patients. Peter Nielsen, CEO of Bio-Path, expressed confidence in prexigebersen's ability to make a difference in patients' lives, especially considering the limited treatment options available.
The interim results also showed that adverse events were consistent with expectations for AML treatment, with fatigue, anemia, and neutropenia being the most common, while febrile neutropenia and sepsis were the most frequent severe adverse events. Encouraged by these findings, Bio-Path plans to continue enrollment in both cohorts, aiming for up to 98 and 54 evaluable patients in Cohorts 1 and 2, respectively.
Conclusion
As investors anticipate further developments, some speculate that the stock could surpass $4.50, considering the positive momentum and limited short shares available, with a barrow fee of 240%. Bio-Path's innovative approach to developing RNAi nanoparticle drugs has positioned it as a key player in the biotechnology sector, with potential implications for the treatment of various cancers.
Bio-Path Holdings，Inc.（納斯達克：BPTH）週一盤前交易中經歷了顯著的上漲，在上週五大幅攀升近7％後。該股票飆升了驚人的62％，在盤前早期達到了3.38美元的高位，而其上週五的價格爲1.93美元。這次漲勢伴隨着駭人聽聞的150萬股的交易量，在延長交易中表明瞭相當樂觀的情緒。
Bio-Path第二階段數據有希望
此次漲勢是在2024年6月1日美國臨床腫瘤學會（ASCO）年會上由Bio-Path提出有希望的第二階段數據之後而來的。公司的首席候選產品prexigebersen（BP1001）在兩個急性髓系白血病（AML）患者報告隊列中展示了引人注目的療效結果。在包括新診斷患者的隊列1中，75％的可評估患者達到了完全緩解（CR），CRh或CRi，而在包括復發/難治患者的隊列2中，55％實現了CR / CRi / CRh。
樂觀的前景
來自德克薩斯大學MD Anderson癌症中心的Maro Ohanian醫生提出了這些數據，並強調了prexigebersen的耐受性以及其解決弱勢癌症患者需求的潛力。Bio-Path的首席執行官Peter Nielsen表示，他對prexigebersen改善患者的生活能力充滿信心，尤其是考慮到有限的治療選擇。
臨時結果還顯示，不良事件與AML治療的預期一致，疲勞，貧血和中性粒細胞減少症是最常見的，而發熱性中性粒細胞減少症和敗血症是最常見的嚴重不良事件。受到這些發現的鼓舞，Bio-Path計劃在兩個隊列中繼續招募，旨在分別在隊列1和2中獲得高達98和54個可評估患者。
結論
隨着投資者期待進一步發展，一些人推測該股票可能會超過4.50美元，考慮到積極的動能和有限的開空股票，借入費用達240％。Bio-Path開發RNAi納米粒子藥物的創新方法將其定位爲生物技術板塊的關鍵參與者，並可能影響各種癌症的治療。
